Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have a Nexplanon implant and are considering tirzepatide for weight management, the most reassuring thing to know is this: unlike oral contraceptives, the implant is not absorbed through the gut, so tirzepatide's effect on gastric emptying does not interfere with how it works. That said, the full picture is worth understanding before you start treatment, because tirzepatide is a prescription-only medicine that requires a clinical assessment to confirm it is right for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A concern that comes up frequently (and understandably) is whether starting tirzepatide will interfere with a hormonal contraceptive implant such as Nexplanon. The worry has a reasonable basis: tirzepatide slows the rate at which the stomach empties, and that change in gastric motility can reduce how well orally-taken medicines are absorbed into the body. For women on the combined oral contraceptive pill or progestogen-only pill, this is clinically relevant.
Nexplanon works differently. It is a small flexible rod inserted just under the skin of the upper arm, and it releases the hormone etonogestrel directly into the surrounding tissue and then into the bloodstream. There is no oral absorption step, no journey through the stomach, and therefore no mechanism by which slowed gastric emptying could diminish its effectiveness. The MHRA's specific guidance on oral contraceptives and tirzepatide simply does not apply to implant users in the same way.
NHS England's guidance on weight-management injections confirms this distinction: it is women using the oral contraceptive pill who are advised to add a non-oral method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase. If you rely on Nexplanon, that particular precaution is not directed at you. It is worth reading the guidance yourself — NHS England's page on weight-management injections sets this out clearly and is updated as clinical thinking evolves.
Tirzepatide is a once-weekly injection sold in the UK under the brand name Mounjaro. It activates two gut-hormone receptors, GIP and GLP-1, which work together to reduce appetite, slow stomach emptying, and support weight loss. You can read more about how it works on the tirzepatide overview page.
The slowing of gastric emptying is useful therapeutically, it is one reason people feel fuller for longer. But it creates a relevant question for any medicine or supplement that relies on consistent oral absorption. Oral contraceptives are absorbed in the gut; if the gut takes longer to process them, peak hormone levels can shift. That is the root of the pill-specific caution.
Nexplanon, by contrast, delivers etonogestrel at a steady, predictable rate through the implant itself. The gastrointestinal system plays no part. A useful one-minute check: look at your contraceptive method and confirm whether it involves swallowing something daily. If it does not (implant, injection, coil, patch) the gastric-emptying concern does not apply to its mechanism of action. That is not a substitute for a clinical conversation, but it helps frame the right question to ask.
For anyone wanting to understand the cost implications of starting treatment, our Mounjaro cost page explains how private pricing works and what a legitimate service includes.
Tirzepatide is not recommended for use during pregnancy or breastfeeding, or for people actively trying to conceive. This applies regardless of which contraceptive method someone uses. If your circumstances change (if you and your partner decide to start trying) that is the moment to contact your prescriber before stopping treatment unilaterally, not after.
The MHRA advises using effective contraception throughout treatment and for a period after stopping. The exact wash-out period is specified in the Patient Information Leaflet and should be confirmed with your prescriber at the time, since it can depend on how long you have been on treatment and the dose you were taking. Our tirzepatide treatment plan page covers what clinical oversight looks like over the course of treatment.
One area sometimes overlooked is how body-composition changes from significant weight loss can affect fertility, cycles may change as weight reduces, and assumptions about fertility should be revisited with a GP if relevant. This is not a concern unique to tirzepatide; it applies to meaningful weight loss by any route. A prescriber who reviews you at each stage of treatment is placed to flag it. At nume, every repeat order is looked at by a GPhC-registered prescriber, not reviewed automatically.
Nexplanon compatibility aside, the broader safety profile of tirzepatide is worth knowing. The most common side effects are gastrointestinal: nausea tends to be most noticeable after a new pen is started or a dose steps up, and it typically eases within a couple of weeks. Constipation, loose stools, and reflux are also reported. The NHS tirzepatide page lists these in plain language alongside the symptoms that warrant prompt medical attention.
More serious but less common concerns include pancreatitis (severe stomach pain that spreads to the back) and gallbladder problems. These do not interact specifically with Nexplanon, but they are part of the full picture any prescriber will cover during your consultation. Anyone with a personal or close family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 will not be suitable for tirzepatide, and those conditions are screened during assessment. If you have a neurological condition such as multiple sclerosis and want to understand whether treatment is appropriate, our tirzepatide and MS page addresses that specific question in detail.
If you are also using HRT alongside your implant, there is a separate but related question about how tirzepatide may affect HRT absorption, our HRT and tirzepatide page covers that in detail. For a broader view of all treatment options available through an online assessment, the weight-loss treatments page is the right starting point. If you have questions before you begin, our team is reachable via the contact page.
Tirzepatide is a prescription-only medicine. A prescriber assesses your full medical picture, including your contraceptive method, before any treatment is approved. Check your eligibility with a free consultation, and if you would like a full summary of the evidence on how tirzepatide supports weight loss, our tirzepatide evidence page brings the clinical data together in one place.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.